BRAF and melanoma: Recently, the results of a triple combination of atezolizumab, vemurafenib, and cobimetinib, in patients with BRAF-mutant melanoma, were reported: the phase III clinical study IMspire 150 showed a significant PFS benefit (15.1 vs. 10.6 months) for patients treated with the triple combination, as compared to those who received vemurafenib and cobimetinib only [71].